RemeGen (HKG:9995, SHA:688331) posted an attributable profit of 4.66 billion yuan in the first half of 2026, rebounding from an attributable loss of 449.57 billion yuan a year ago.
Earnings per share came in at 8.32 yuan, compared with a loss per share of 0.83 yuan a year earlier, according to a Monday filing with the Hong Kong Exchange.
Revenue surged year over year to 5.85 billion yuan from 1.09 billion, the biopharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.